Figure 1 | British Journal of Cancer

Figure 1

From: Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

Figure 1

Individual plasma mapatumumab concentrations. Plasma mapatumumab concentrations observed for individual subjects after two 20 mg kg−1 mapatumumab intravenous infusion doses given 14 days apart, with 10 mg kg−1 mapatumumab intravenous infusion doses given every 14 days thereafter, with the expected minimum to maximum concentration range based on phase 1 study results.

Back to article page